It’s the battle of the boosters. A day after Sanofi and GlaxoSmithKline said their COVID-19 shot works well as a booster for other shot regimens, Valneva and Arcturus Therapeutics are adding to the…
MedCity Influencers, Health Tech Unless we’re careful, digital health will go down the same path as our legacy health systems as the rush to compete prompts consolidation that misaligns incentives. https://medcitynews.com/author/andrewle
Six months after Biogen was awarded regulatory approval for its Alzheimer’s disease drug Aduhelm, the company the company is laying out a timeline for the post-marketing study to confirm whether the…
Eric Johnson Eric Johnson is the founder and CEO of membersy, a digital health company democratizing access to quality, affordable dental care through subscription-based dentistry. While building his career in the dental care space, Eric founded membersy in 2015 with the mission of helping dental professionals take back the dental care narrative from big insurance …
Unless we’re careful, digital health will go down the same path as our legacy health systems as the rush to compete prompts consolidation that misaligns incentives.
Technology’s proliferation in the next year can make this system even more effective, helping patients and providers thrive in 2022.
Omicron is forcing Americans to rethink some — but not all — of their holiday plans and precautions during the pandemic.
The FDA has openly suggested that a brand-name drug maker, Endo International, attempted to delay competition on a medicine.
This will greatly improve access, but not for everyone,” says Daniel Grossman, a University of California, San Francisco researcher.
The study will enroll more than 1,300 patients with early-stage Alzheimer’s from the U.S. and internationally, the company said.
